NORTH CHICAGO, Ill., June 26, 2020   – Allergan, an AbbVie Company (NYSE: ABBV), and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced that the U.S.

Zurich-Schlieren, Switzerland, May 15, 2020.   Molecular Partners AG  (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, today announced the presentation of preclinical data from three of the company’s

Research & Development Highlights: Abicipar in neovascular wet age-related macular degeneration (nAMD): Presentation of MAPLE data at the 2020 Angiogenesis, Exudation, and Degeneration symposium showed lower rates of intra-ocular inflammation than the rate observed in Phase 3 studies, as well as no

DARPin® antiviral candidates demonstrate low picomolar potency in live virus assay Candidate construction complete; two candidates ready for preclinical development & manufacturing Therapeutic profile of a highly potent antiviral biologic with a long half-life supports both a prophylactic and

Zurich-Schlieren, Switzerland, April 29, 2020. At today’s Annual General Meeting of Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein therapeutics known as DARPin® therapeutics, the shareholders of the company approved all

First trispecific anti-COVID-19 therapeutic program: targets three parts of the viral “spike” protein with one drug candidate for broad inhibition of infection and mitigation of future drug resistance Initial testing performed in collaboration with the Swiss Federal Office for Civil Protection

Zurich-Schlieren, Switzerland, March 25, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published the invitation to the Annual General Meeting 2020. The Annual General Meeting will be held on

Zurich-Schlieren, Switzerland, March 20, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today published its audited Financial Results for 2019 and the company’s 2019 Annual Report.

Zurich-Schlieren, Switzerland, February 24, 2020.  Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of drugs known as DARPin® therapies, today announced that senior management will present at two upcoming healthcare investor conferences.

Sandip Kapadia, Michael Vasconcelles and Vito J. Palombella nominated for election to the Board of Directors of Molecular Partners at the upcoming Annual General Meeting Nominees bring extensive expertise in the fields of oncology drug discovery, translational science, clinical development,